BrightView offers personalized outpatient and intensive outpatient treatment programs that work. It takes a lot of courage to talk about addiction. That’s why BrightView is changing the conversation about addiction treatment. BrightView treats the disease of addiction with effective medicines that provide each patient real help with withdrawal cravings and other symptoms. We offer comprehensive treatment programs that are scientifically proven and tailored to your needs.
For several decades, opioid use disorder has emerged in the U.S. as a primary medical problem that has affected millions of lives. People from culturally different backgrounds have all been impacted by the dangers of opioid misuse and opioid dependence. However, addiction is a treatable illness whose progression can be halted through participation in a recovery process. With opioid addiction in particular, the recovery process can be greatly aided through the use of medication-assistance like that offered with buprenorphine and suboxone. Buprenorphine is the active ingredient in suboxone and subutex. Years of research has demonstrated the essential role that buprenorphine-based medications can play in stabilizing patients who are suffering with opioid withdrawal symptoms.
Lexington offers local citizens a number of doctors authorized to provide prescriptions for buprenorphine to manage opioid dependency and associated opioid withdrawal. Buprenorphine is the primary ingredient in suboxone that eliminates a patient’s opioid withdrawal symptoms such as nausea, diarrhea, vomiting, insomnia, and chills. Doctors authorized to write suboxone prescriptions have obtained training in the safe use of suboxone. Suboxone (buprenorphine) has acquired a good reputation in the addiction treatment community due to its desirable safety profile and usefulness in alleviating opioid withdrawal sickness.
If you are a local medical professional treating Lexington area residents, you may purchase a featured listing at the top of this page insuring that your treatment services will be found by prospective patients searching our website for quality suboxone treatment. Suboxone (buprenorphine) has become a primary therapeutic option for opioid addicted individuals. Methadone.US is striving to educate the general public on the diversity of opioid replacement choices available in their region.
When it comes to addiction, reactions and opinions are often intense. Addiction is a devastating illness that can rapidly derail a person’s life, and seriously impact the lives of those around them.
Sadly, addiction leads people to behave in ways that make no sense to their family, friends, and co-workers. Therein lies an important part of the problem. Family feel confused, angry, and fearful as their loved one tumbles down the hill of active addiction.
When it comes to something as perplexing as drug addiction, grasping for answers is an understandable reflex for family and friends. What family often don’t comprehend is the power of physical dependency to opioids and the severe sickness that results from opioid withdrawal.
Family and others incorrectly assume that mere “choice” is all that’s needed to overcome the addiction. When the addict fails to remain drug free, harsh judgment by others usually follows.
Halting withdrawal sickness is a paramount step for an opioid addicted person. This cannot be overstated. As long as a person is suffering from severe opioid withdrawal, their ability to think and “choose” logically is greatly impaired.
Statistically, individuals who utilize medication-assisted treatment (like methadone) are far more likely to avoid incarceration, a continued downward spiral, or death by overdose. Medication assistance successfully removes debilitating withdrawal sickness so that the addicted person can experience greater clarity of thought and the ability to make more sound decisions that lead to improved quality of life.
If you are a skeptic about methadone or suboxone, you may think “they’re just trading one drug for another”. This is not true. People, once therapeutically stabilized on methadone or suboxone, do not get high from the medication. Health generally improves, and the person is able to function much better on the job and at home. This brings hope. It offers a new opportunity for further recovery.
When you care about a person’s survival, one more chance to help them can be quite valuable. Don’t let judgment or excessive skepticism get in the way. Medication-assistance in opioid recovery is effective for many people, and it has been the life saving next step that some never got the chance to take.
Like most states, Oregon is in need of quality treatment options for opioid-addicted individuals who are ready for recovery.
This article, in the Hillsboro News-Times, features the recent approval by Washington County commissioners to add a new methadone clinic in Hillsboro, Oregon.
Acadia Healthcare is aiming to establish the new methadone clinic in Hillsboro in order to better serve the local community. Acadia already operate a mobile unit in the general area as well as a comprehensive treatment center (CTC) in nearby Tigard located about 20 miles away.
The commissioners voted 5-0 to approve the proposed site which will be on the local bus route thereby providing improved access. The article mentions that Oregon presently has 17 operational methadone clinics serving the state, where fentanyl, opiates, and other substances are causing a grave overdose crisis.
Having local opioid treatment available is a critically important step in saving lives and providing hope to patients and families. Methadone has been proven to decrease opioid use, reduce relapse risks & overdose deaths, as well as increase employment and overall health. Clinics offering medication-assisted treatment (MAT), like methadone and buprenorphine, are forging a new path to safety for those people once stuck in active addiction.
There’s a new spin being proposed on the dispensing of methadone to Opioid Use Disorder (OUD) patients. A federally-funded project is underway between Scene Health and The University of Washington in which patients video themselves taking their daily methadone dose, and then submit that video to the treatment provider.
The project is evaluating this new modified approach that falls somewhere between in-person daily dosing and unsupervised take home dosing.
This new approach is currently being referred to as Video DOT (video direct observation therapy) and has been successfully implemented with other health issues including hepatitis C, asthma, and diabetes.
While this experiment seems appealing at first glance, it does raise legitimate questions about the ability to insure proper safety protocols with the provision of methadone medication to new patients. The project may possibly demonstrate the usefulness of Video DOT methadone dosing. But assuming this new approach one day becomes common practice, it will be important that physicians or clinics have in place a procedure for quickly reclaiming methadone doses that are not ingested on schedule.
Imagine a new patient receives 7 take home doses of methadone, but then only sends in the required video of their medication use on day one. At what point does the prescribing clinic intervene, and how will the unaccounted for doses be retrieved?
Approved Opioid Treatment Programs currently have “callback” procedures in which stable patients are randomly selected to return to their home clinic with their unused take home doses. This allows the clinic medical staff to perform a medication count, and it acts as a safeguard to insure patients are taking their medication as prescribed.
Patients who have earned take home privileges through months of treatment progress are less inclined to divert or misuse methadone than someone who just started treatment. New patients must be inducted gradually on a stabilizing dose of methadone. And time is typically needed to help these patients adjust to methadone while eliminating use of all other illicit substances. This is where the benefit of a structured treatment program is most relevant. OTP’s provide extremely valuable life management skills training in conjunction with medication therapy.
It remains to be seen if “easy access” to methadone is truly an advancement in care, or a step backwards in accountability & safety for patients and the public.
Historically, access to methadone for the treatment of opioid addiction has been through enrollment in a local clinic licensed to dispense methadone. As a result of Covid restrictions, some of these clinic regulations were relaxed. For example, many patients across the U.S. were allowed to begin receiving take home doses of methadone as a result of Covid lockdowns and decreased clinic access.
Critics have begun to express the belief that clinic restrictions are cumbersome and that methadone should be made available for pick-up at local pharmacies. On the other hand, the concern remains that methadone can be misdirected or mishandled thus reinforcing the need for close supervision, particularly in the early phases of opioid treatment. Decades of research has shown that taken under proper supervision, methadone’s safety profile is excellent.
In this recent era of contaminated street opiates and overdose concerns, it is clear that methadone is a phenomenally effective medication for promoting health, well-being, and physical safety.
Mark Parrino, president of the American Association for the Treatment of Opioid Dependence, recently shared that deregulation of methadone would likely increase the diversion of methadone and methadone-related overdose deaths.
Following a period of stability, most U.S. clinics do allow patients to begin dosing at home with methadone. This system of care is working well throughout the country where methadone is readily available. However, many U.S. citizens are still lengthy distances from methadone-approved clinics. So, the challenge continues to link those with opioid addiction to effective resources in their local community. Legislators are presently examining a range of options as the opioid epidemic marches on.